ArticlePloS one2015
Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- PTEN-Long inhibits the biological behaviors of glioma cells.American journal of translational research · 2024Article
- Purified PTEN-Long Induces Liver Cancer Cells to Undergo Autophagy and Apoptosis.Frontiers in surgery · 2022Article
- Hypoxic Microenvironment-Induced Reduction in PTEN-L Secretion Promotes Non-Small Cell Lung Cancer Metastasis through PI3K/AKT Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Review
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- Article
- Expression of PTEN-long nephritis and its effect on renal inflammation.Experimental and therapeutic medicine · 2019Article
- Bayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics.Journal of the American Statistical Association · 2019Article
- Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth.Gene therapy · 2018Article
- PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy.Cell research · 2018Article
- Clinical implications of PTEN loss in prostate cancer.Nature reviews. Urology · 2018Review
- Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model.Cytotechnology · 2018Article
- PTEN-L promotes type I interferon responses and antiviral immunity.Cellular & molecular immunology · 2018Article
- Expression of PTEN-long mediated by CRISPR/Cas9 can repress U87 cell proliferation.Journal of cellular and molecular medicine · 2017Article
- PTEN proteoforms in biology and disease.Cellular and molecular life sciences : CMLS · 2017Review
- Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma.Oncotarget · 2016Article
- Controlling PTEN (Phosphatase and Tensin Homolog) Stability: A DOMINANT ROLE FOR LYSINE 66.The Journal of biological chemistry · 2016Article
- Systematic analysis of the PTEN 5' leader identifies a major AUU initiated proteoform.Open biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PTEN-Long is a translational variant of PTEN (Phosphatase and Tensin Homolog). Like PTEN, PTEN-Long is able to antagonize the PI3K-Akt pathway and inhibits tumor growth. In this study, we investigated the role PTEN-Long plays in the development and progression of clear cell renal cell carcinoma (ccRCC) and explored the therapeutic possibility using proteinaceous PTEN-Long to treat ccRCC. We found that the protein levels of PTEN-Long were drastically reduced in ccRCC, which was correlated with increased levels of phosphorylated Akt (pAkt). Gain of function experiments showed overexpression of PTEN-Long in the ccRCC cell line 786-0 suppressed PI3K-Akt signaling, inhibited cell proliferation, migration and invasion, and eventually induced cell death. When purified PTEN-Long was added into cultured 786-0 cells, it entered cells, blocked Akt activation, and induced apoptosis involving Caspase 3 cleavage. Furthermore, PTEN-Long inhibited proliferation of 786-0 cells in xenograft mouse model. Our results implicated that understanding the roles of PTEN-Long in renal cell carcinogenesis has therapeutic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.